SCHEMBL3279870

SCHEMBL3279870

COC1C[C@H](n2cnc3c(=O)[nH]c(N)nc32)O[C@@H]1CO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
HPGD P15428 1/20 0.54
KDM4E B2RXH2 1/20 0.54
HINT1 P49773 1/20 0.48
POLA1 P09884 1/20 0.47
STING1 Q86WV6 2/20 0.47
PDE3A Q14432 2/20 0.47
PDE3B Q13370 1/20 0.47
HPRT1 P00492 1/20 0.47
P2RY2 P41231 1/20 0.47
P2RY4 P51582 1/20 0.47
P2RY6 Q15077 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
PNP P00491 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
PDE4D Q08499 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279868 1.00 POLB (0.56) POLBHPGDKDM4EHINT1POLA1
SCHEMBL16359975 1.00 POLB (0.56) POLBHPGDKDM4EHINT1POLA1
SCHEMBL4579814 0.91 POLB (0.56) POLBHPGDKDM4EHINT1STING1
SCHEMBL12087555 0.91 POLB (0.54) POLBHPGDKDM4EHINT1STING1
SCHEMBL10446713 0.91 POLB (0.56) POLBHPGDKDM4EHINT1STING1
SCHEMBL4579809 0.91 POLB (0.56) POLBHPGDKDM4EHINT1STING1
SCHEMBL12015126 0.91 POLB (0.54) POLBHPGDKDM4EHINT1STING1
SCHEMBL16359956 0.90 KDM4E (0.57) POLBHPGDKDM4EHINT1POLA1
SCHEMBL19033325 0.90 POLB (0.56) POLBHPGDKDM4EHINT1POLA1
SCHEMBL14614376 0.90 POLB (0.56) POLBHPGDKDM4EHINT1STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000900-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS INC (US) 2022-01-06 US disclosed
US-10933079-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2021-03-02 US disclosed
US-20200215092-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. 2020-07-09 US disclosed
US-10456415-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2019-10-29 US disclosed
US-20170035794-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. 2017-02-09 US disclosed
US-9480698-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2016-11-01 US disclosed
US-9358248-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
US-20160130296-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. 2016-05-12 US disclosed
EP-2944646-A1 Oligonucleotide analogues incorporating 5-aza-cytosine therein Astex Pharmaceuticals, Inc. (US) 2015-11-18 EP disclosed
US-20130236536-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein ASTEX PHARMACEUTICALS, INC. (US) 2013-09-12 US disclosed
US-8461123-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein ASTEX PHARMACEUTICALS, INC. (US) 2013-06-11 US disclosed
US-20100215729-A1 OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN SUPERGEN, INC. 2010-08-26 US disclosed
US-7700567-B2 methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders SUPERGEN, INC. (US) 2010-04-20 US disclosed
US-20070072796-A1 methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders ASTEX PHARMACEUTICALS, INC. 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200215092-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-20220000900-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-20130236536-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-10456415-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-20160130296-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-10933079-B2 Oligonucleotide analogues incorporating 5-aza-cytosine therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-20170035794-A1 Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-20100215729-A1 OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN DCTD, DNMT3B, NT5C3B POLB 52/4885HPGD 1248/4885KDM4E 1041/4885
US-20070072796-A1 methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders DCTD, DNMT3B, NT5C3B POLB 37/4885HPGD 1087/4885KDM4E 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.